Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cethromycin - Advanced Life Sciences/ Abbott Laboratories

Drug Profile

Cethromycin - Advanced Life Sciences/ Abbott Laboratories

Alternative Names: A-195773; A-195773-0; Abbott-195773; ABT 773; Restanza

Latest Information Update: 06 May 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Advanced Life Sciences; National Institute of Allergy and Infectious Diseases; Taisho Pharmaceutical; United States Army Medical Research Institute of Infectious Diseases; Walter Reed Army Institute of Research
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Plague; Tularaemia; Anthrax
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Anthrax; Community-acquired pneumonia; Gonorrhoea; Malaria; Melioidosis; Plague; Tularaemia
  • Discontinued Acute sinusitis; Bacterial infections; Clostridium difficile infections; Toxoplasmosis

Most Recent Events

  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Canada (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Europe (PO)
  • 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top